Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis-Reference-Cited by-同舟云学术

Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis

Published:2022-01-24 Issue:2 Volume:22 Page:229-235
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Latif Farah¹,Bint Abdul Jabbar Hira²,Malik Hamna³,Sadaf Humaira⁴,Sarfraz Azza⁵^ORCID,Sarfraz Zouina¹^ORCID,Cherrez-Ojeda Ivan⁶^ORCID

Affiliation:

1. Research and Publications, Fatima Jinnah Medical University, Lahore, Pakistan

2. Research, King Edward Medical University, Lahore, Pakistan

3. Research, Services Institute of Medical Sciences, Lahore, Pakistan

4. Internal Medicine, University of Texas Health Science Centers, McGovern Medical School, Houston, Texas, USA

5. Pediatrics and Child Health, The Aga Khan University, Karachi, Pakistan

6. Allergy and Pulmonology, Universidad Espíritu Santo, Ecuador

Funder

funding

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2022.2023011

Reference24 articles.

1. Anders C, Carey LA. Understanding and treating triple-negative breast cancer. Vol. 22. New York, USA: Oncology (Williston Park); 2008. p. 1233–1243.

2. Triple-Negative Breast Cancer

3. The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity

4. Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor

5. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarker-based immunotherapy in breast cancer;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Heterogeneity in the Primary Lesions of invasive micropapillary breast carcinoma.;Current Problems in Cancer: Case Reports;2024-09

3. Preliminary Research of Radiolabeled Atezolizumab for the Noninvasive Evaluation of TNBC PD‐L1 Expression In Vivo;Journal of Labelled Compounds and Radiopharmaceuticals;2024-08-30

4. Identification of the novel exhausted T cell CD8 + markers in breast cancer;Scientific Reports;2024-08-19

5. Biomarkers in the Immuno-oncology Interface of Triple Negative Breast Cancer: A Scoping Review with Perioperative Considerations;Current Oncology Reports;2024-07-06